UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of March 2019

Commission File Number 

001-37846

 

CELLECT BIOTECHNOLOGY LTD.

(Translation of registrant’s name into English)

 

23 Hata’as Street

Kfar Saba, Israel 44425

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐

 

 

 

 

 

 

Attached hereto as Exhibit 99.1 and incorporated by reference herein is a press release issued by the Registrant entitled “Cellect Announces Positive Results from Cell2in Collaboration Showing Significant Improvement in Expansion Rate and Function of Stem Cells.”

 

Exhibit

 

99.1 Press Release, dated March 11, 2019

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Cellect Biotechnology Ltd.
     
Date: March 11, 2019 By: /s/ Eyal Leibovitz
    Name: Eyal Leibovitz
  Title:   Chief Financial Officer

 

 

2

 

Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Cellect Biotechnology Charts.
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Cellect Biotechnology Charts.